GE HealthCare Technologies Inc.

The filings show a company whose annual top line grew steadily while the first quarter of 2026 showed clear pressure. For fiscal 2025, revenues were $20.62 billion against $19.67 billion in 2024, a gain of about 4.8%, and net income rose to $2.08 billion from $1.99 billion. The 10-Q for the period ended March 31, 2026 tells a more difficult near-term story: operating income of $515 million fell 18.1% from $629 million, and net income attributable to GE HealthCare fell to $389 million from $564 million. Management attributes about $90 million of operating income impact in that quarter to tariffs, mainly the bilateral U.S. and Chinese tariffs. The MD&A also discusses the Supreme Court ruling on IEEPA tariffs and a new refund process, but the timing and amount of any refund remain uncertain, so readers may want to look at how management reports any refund in later filings. Segment results are uneven: PDx revenue rose 21.7% to $770 million, while PCS fell 6.5% to $704 million. Russia and Ukraine exposure is modest in the company's own figures, with $194 million of assets and $54 million of quarterly revenue, but export licensing still limits supply in some cases. Liabilities rose from $24.44 billion at the end of 2024 to $26.31 billion at the end of 2025, about 71% of total assets, and readers may want to weigh that alongside the debt covenant language in the forward-looking statements. No Beneish M-Score, Piotroski F-Score, Altman Z-Score, or Fog Index values are on file for this review, so this synthesis does not rely on any forensic score. Taken together, the filings show growing annual revenue and a weaker first quarter of 2026, driven largely by tariff costs and organic growth of only 2.9%.

Catalyst.Management points to growth in PDx, Imaging, and AVS as the main drivers. For the quarter ended March 31, 2026, total revenues rose 7.4% to $5,131 million, with PDx up 21.7% to $770 million, AVS up 8.2% to $1,341 million, and Imaging up 7.4% to $2,299 million. Product sales increased 7.3% and service sales rose 7.5%, which the company ties to new and existing customer contractual agreements. Fiscal 2025 revenue of $20.62 billion was also above the 2024 level of $19.67 billion. Part of the reported growth came from favorable foreign currency effects, and organic growth for the quarter was 2.9%, so reported growth overstates the underlying pace.

Hidden risk.The most material tension is between reported and underlying growth. First-quarter 2026 revenue rose 7.4% as reported but only 2.9% organically, while operating income fell 18.1% to $515 million from $629 million. The MD&A says tariffs materially affected operating income by approximately $90 million and cash flows by approximately $110 million in that quarter, and management does not expect its mitigation actions to fully offset the added costs. Refunds of tariffs imposed under IEEPA are described as uncertain in timing and amount, so no refund should be treated as settled. Management also cites competition from local companies and volume-based procurement policies in China that have affected orders and revenues. A reader focused on headline revenue growth could miss the profit squeeze.